Agenus Inc. (NASDAQ: AGEN) has witnessed a notable upsurge in its stock position, marking a gain of 14.09% and reaching $7.37. This increase in AGEN stock value closely follows the disclosure of an imminent presentation concerning a significant clinical trial.
Earlier today, Agenus (AGEN) unveiled plans to present findings from a Phase 1b investigation of botensilimab alongside balstilimab (“BOT/BAL”) for individuals grappling with relapsed or refractory microsatellite stable colorectal cancer devoid of active liver metastases (r/r MSS CRC NLM).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Agenus will be presenting at the American Society of Clinical Oncology (ASCO) Meeting set to take place in Chicago, Illinois, from May 31 to June 4, 2024.The poster presentation will specifically address a sub-analysis of the r/r MSS CRC cohort from the Phase 1b study. This analysis was conducted to explore potential correlations between treatment outcomes and specific metastatic sites in patients without active liver metastases.
Agenus also recently disclosed updated findings from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC lacking microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These results complement the noteworthy clinical efficacy demonstrated by BOT/BAL across nine diverse cancer types within Agenus’ extensive clinical development program.
In the Phase 1 trial involving 77 patients with refractory MSS-CRC devoid of active liver metastases, an overall response rate (ORR) of 23% was observed following a median follow-up of 13.6 months as of the data cutoff date of March 1, 2024. Among the 18 responders, the median reaction time had not yet been attained.
With a median overall survival (OS) clocking in at 21.2 months, prognostications indicate that OS rates at 12 and 18 months are expected to reach 71% and 62%, respectively. With Phase 2 trial enrollment now wrapped up, the corporation aims to engage in discussions with the FDA (U.S. Food and Drug Administration) concerning the upbeat interim results.
These findings underscore the efficacy of BOT/BAL in addressing metastatic colorectal cancer (CRC), standing as the second most prevalent cause of cancer-related mortality in the United States. Pending scheduled consultations with the FDA, Agenus aims to submit a Biologics License Application (BLA) for BOT/BAL in refractory MSS CRC later this year.
Furthermore, Agenus plans to present comprehensive Phase 2 efficacy findings, encompassing response durability and updated Phase 1 survival data, at a prominent medical conference in the latter half of 2024. This expanding body of clinical evidence underscores the significant promise of BOT/BAL in reshaping the treatment landscape for challenging solid tumors.
